Asterias Biotherapeutics (AST) Misses Q4 EPS by 5c

Asterias Biotherapeutics (NYSE: AST) reported Q4 EPS of ($0.20), $0.05 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $2.5 million.

For earnings history and earnings-related data on Asterias Biotherapeutics (AST) click here.

You May Also Be Interested In

• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
• Credo Technology Group Holding (CRDO) Tops Q1 EPS by 4c; offers guidance
• GitLab Inc (GTLB) Tops Q2 EPS by 7c, Beats on Revenue